Abstract
The Indian generic drug manufacturer Cipla Ltd announced at the beginning of February 2001 that it will supply triple-drug therapy for HIV to the world's poor at a cost of <$1 a day, significantly undercutting multinational companies. The company, which makes cheap copies of drugs that are patent-protected in other countries, is offering stavudine, lamivudine and nevirapine to the international charity Medecins Sans Frontieres (MSF) for $350 per patient per year, and to governments for $600; their normal price is $1200 per patient per year. MSF said the offer showed that its target of $200 per year was almost within reach, and it called on western pharmaceutical companies to match the Cipla price. The same combination therapy would cost $10 400 per year in the USA. CK
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
